Treatment of frostbite with intra-arterial prostaglandin E1

R. A. Yeager, T. W. Campion, J. C. Kerr, R. W. Hobson, T. G. Lynch

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Prostaglandin E1 (PGE1) is a vasodilator that inhibits platelet aggregation. Its use has been effective intra-arterially in treating ischemic peripheral vascular disease. Its potentially beneficial effect in treating frostbite injuries has not been studied and prompted this investigation. A standard frostbite injury was induced by immersing the hindlimbs of New Zealand white rabbits in an ethylene glycol bath maintained at -15 C. Forty animals were separated into eight equal groups (N = 5). Groups I through V were allowed to slowly rewarm at room temperature (21 - 22 C), while Groups VI through VIII underwent rapid rewarming in a water bath at 42 ± 1 C. Groups I and VI received no further treatment. Groups II and VII received intra-arterial bolus injections of saline. Group III received intra-arterial bolus injections of reserpine (2.5 x 10-3 mg/kg-1). Group IV received intra-arterial bolus injections of PGE1 (10-1 μg/kg-1). Groups V and VIII received 3-hour intra-arterial infusions of PGE1 (10-1 μg/kg-1 min-1). Tissue loss was graded numerically after 30 days. Group V (slow rewarming plus 3-hour PGE1 infusion) had significantly (P < 0.5) less tissue loss than Group I (slow rewarming alone) and Group II (slow rewarming plus saline). Group V was not significantly different from Groups VI through VIII (rapid rewarming). Group III (slow rewarming plus bolus reserpine) and Group IV (slow rewarming plus bolus PGE1) were not significantly different from Group I (slow rewarming alone). The data suggest a clinical application for the use of PGE1 in frostbite patients who have not undergone rapid rewarming.

Original languageEnglish (US)
Pages (from-to)665-667
Number of pages3
JournalAmerican Surgeon
Volume49
Issue number12
StatePublished - Dec 1 1983

Fingerprint

Frostbite
Rewarming
Alprostadil
Intra-Arterial Injections
Therapeutics
Reserpine
Baths
Intra Arterial Infusions
Ethylene Glycol
Peripheral Vascular Diseases
Wounds and Injuries
Hindlimb
Vasodilator Agents
Platelet Aggregation
Rabbits

ASJC Scopus subject areas

  • Surgery

Cite this

Yeager, R. A., Campion, T. W., Kerr, J. C., Hobson, R. W., & Lynch, T. G. (1983). Treatment of frostbite with intra-arterial prostaglandin E1. American Surgeon, 49(12), 665-667.

Treatment of frostbite with intra-arterial prostaglandin E1. / Yeager, R. A.; Campion, T. W.; Kerr, J. C.; Hobson, R. W.; Lynch, T. G.

In: American Surgeon, Vol. 49, No. 12, 01.12.1983, p. 665-667.

Research output: Contribution to journalArticle

Yeager, RA, Campion, TW, Kerr, JC, Hobson, RW & Lynch, TG 1983, 'Treatment of frostbite with intra-arterial prostaglandin E1', American Surgeon, vol. 49, no. 12, pp. 665-667.
Yeager RA, Campion TW, Kerr JC, Hobson RW, Lynch TG. Treatment of frostbite with intra-arterial prostaglandin E1. American Surgeon. 1983 Dec 1;49(12):665-667.
Yeager, R. A. ; Campion, T. W. ; Kerr, J. C. ; Hobson, R. W. ; Lynch, T. G. / Treatment of frostbite with intra-arterial prostaglandin E1. In: American Surgeon. 1983 ; Vol. 49, No. 12. pp. 665-667.
@article{b1cc18882c364f1baf2b30a8cddf3ac5,
title = "Treatment of frostbite with intra-arterial prostaglandin E1",
abstract = "Prostaglandin E1 (PGE1) is a vasodilator that inhibits platelet aggregation. Its use has been effective intra-arterially in treating ischemic peripheral vascular disease. Its potentially beneficial effect in treating frostbite injuries has not been studied and prompted this investigation. A standard frostbite injury was induced by immersing the hindlimbs of New Zealand white rabbits in an ethylene glycol bath maintained at -15 C. Forty animals were separated into eight equal groups (N = 5). Groups I through V were allowed to slowly rewarm at room temperature (21 - 22 C), while Groups VI through VIII underwent rapid rewarming in a water bath at 42 ± 1 C. Groups I and VI received no further treatment. Groups II and VII received intra-arterial bolus injections of saline. Group III received intra-arterial bolus injections of reserpine (2.5 x 10-3 mg/kg-1). Group IV received intra-arterial bolus injections of PGE1 (10-1 μg/kg-1). Groups V and VIII received 3-hour intra-arterial infusions of PGE1 (10-1 μg/kg-1 min-1). Tissue loss was graded numerically after 30 days. Group V (slow rewarming plus 3-hour PGE1 infusion) had significantly (P < 0.5) less tissue loss than Group I (slow rewarming alone) and Group II (slow rewarming plus saline). Group V was not significantly different from Groups VI through VIII (rapid rewarming). Group III (slow rewarming plus bolus reserpine) and Group IV (slow rewarming plus bolus PGE1) were not significantly different from Group I (slow rewarming alone). The data suggest a clinical application for the use of PGE1 in frostbite patients who have not undergone rapid rewarming.",
author = "Yeager, {R. A.} and Campion, {T. W.} and Kerr, {J. C.} and Hobson, {R. W.} and Lynch, {T. G.}",
year = "1983",
month = "12",
day = "1",
language = "English (US)",
volume = "49",
pages = "665--667",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "12",

}

TY - JOUR

T1 - Treatment of frostbite with intra-arterial prostaglandin E1

AU - Yeager, R. A.

AU - Campion, T. W.

AU - Kerr, J. C.

AU - Hobson, R. W.

AU - Lynch, T. G.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - Prostaglandin E1 (PGE1) is a vasodilator that inhibits platelet aggregation. Its use has been effective intra-arterially in treating ischemic peripheral vascular disease. Its potentially beneficial effect in treating frostbite injuries has not been studied and prompted this investigation. A standard frostbite injury was induced by immersing the hindlimbs of New Zealand white rabbits in an ethylene glycol bath maintained at -15 C. Forty animals were separated into eight equal groups (N = 5). Groups I through V were allowed to slowly rewarm at room temperature (21 - 22 C), while Groups VI through VIII underwent rapid rewarming in a water bath at 42 ± 1 C. Groups I and VI received no further treatment. Groups II and VII received intra-arterial bolus injections of saline. Group III received intra-arterial bolus injections of reserpine (2.5 x 10-3 mg/kg-1). Group IV received intra-arterial bolus injections of PGE1 (10-1 μg/kg-1). Groups V and VIII received 3-hour intra-arterial infusions of PGE1 (10-1 μg/kg-1 min-1). Tissue loss was graded numerically after 30 days. Group V (slow rewarming plus 3-hour PGE1 infusion) had significantly (P < 0.5) less tissue loss than Group I (slow rewarming alone) and Group II (slow rewarming plus saline). Group V was not significantly different from Groups VI through VIII (rapid rewarming). Group III (slow rewarming plus bolus reserpine) and Group IV (slow rewarming plus bolus PGE1) were not significantly different from Group I (slow rewarming alone). The data suggest a clinical application for the use of PGE1 in frostbite patients who have not undergone rapid rewarming.

AB - Prostaglandin E1 (PGE1) is a vasodilator that inhibits platelet aggregation. Its use has been effective intra-arterially in treating ischemic peripheral vascular disease. Its potentially beneficial effect in treating frostbite injuries has not been studied and prompted this investigation. A standard frostbite injury was induced by immersing the hindlimbs of New Zealand white rabbits in an ethylene glycol bath maintained at -15 C. Forty animals were separated into eight equal groups (N = 5). Groups I through V were allowed to slowly rewarm at room temperature (21 - 22 C), while Groups VI through VIII underwent rapid rewarming in a water bath at 42 ± 1 C. Groups I and VI received no further treatment. Groups II and VII received intra-arterial bolus injections of saline. Group III received intra-arterial bolus injections of reserpine (2.5 x 10-3 mg/kg-1). Group IV received intra-arterial bolus injections of PGE1 (10-1 μg/kg-1). Groups V and VIII received 3-hour intra-arterial infusions of PGE1 (10-1 μg/kg-1 min-1). Tissue loss was graded numerically after 30 days. Group V (slow rewarming plus 3-hour PGE1 infusion) had significantly (P < 0.5) less tissue loss than Group I (slow rewarming alone) and Group II (slow rewarming plus saline). Group V was not significantly different from Groups VI through VIII (rapid rewarming). Group III (slow rewarming plus bolus reserpine) and Group IV (slow rewarming plus bolus PGE1) were not significantly different from Group I (slow rewarming alone). The data suggest a clinical application for the use of PGE1 in frostbite patients who have not undergone rapid rewarming.

UR - http://www.scopus.com/inward/record.url?scp=0021068624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021068624&partnerID=8YFLogxK

M3 - Article

C2 - 6546186

AN - SCOPUS:0021068624

VL - 49

SP - 665

EP - 667

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 12

ER -